These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21812736)

  • 21. Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study.
    Saggar R; Khanna D; Shapiro S; Furst DE; Maranian P; Clements P; Abtin F; Dua S; Belperio J; Saggar R
    Arthritis Rheum; 2012 Dec; 64(12):4072-7. PubMed ID: 22777623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An update on the use of ambrisentan in pulmonary arterial hypertension.
    D'Alto M
    Ther Adv Respir Dis; 2012 Dec; 6(6):331-43. PubMed ID: 22933513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
    McGoon MD; Frost AE; Oudiz RJ; Badesch DB; Galie N; Olschewski H; McLaughlin VV; Gerber MJ; Dufton C; Despain DJ; Rubin LJ
    Chest; 2009 Jan; 135(1):122-129. PubMed ID: 18812445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
    Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
    Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic evaluation of ambrisentan.
    Buckley MS; Wicks LM; Staib RL; Kirejczyk AK; Varker AS; Gibson JJ; Feldman JP
    Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):371-80. PubMed ID: 21299444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G; Mehta S
    Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials).
    Maron BA; Waxman AB; Opotowsky AR; Gillies H; Blair C; Aghamohammadzadeh R; Loscalzo J; Leopold JA
    Am J Cardiol; 2013 Sep; 112(5):720-5. PubMed ID: 23751938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension.
    Ben-Yehuda O; Pizzuti D; Brown A; Littman M; Gillies H; Henig N; Peschel T
    J Am Coll Cardiol; 2012 Jul; 60(1):80-1. PubMed ID: 22578922
    [No Abstract]   [Full Text] [Related]  

  • 29. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.
    Walker G; Mandagere A; Dufton C; Venitz J
    Br J Clin Pharmacol; 2009 May; 67(5):527-34. PubMed ID: 19552747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy and safety of ambrisentan therapy in Chinese patients with pulmonary hypertension].
    Chen FD; Zhou DX; Di RM; Zou Y; Wei W; Liu XB
    Zhonghua Yi Xue Za Zhi; 2013 Sep; 93(34):2736-8. PubMed ID: 24360110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.
    Venitz J; Zack J; Gillies H; Allard M; Regnault J; Dufton C
    J Clin Pharmacol; 2012 Dec; 52(12):1784-805. PubMed ID: 22205719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study).
    Pan Z; Marra AM; Benjamin N; Eichstaedt CA; Blank N; Bossone E; Cittadini A; Coghlan G; Denton CP; Distler O; Egenlauf B; Fischer C; Harutyunova S; Xanthouli P; Lorenz HM; Grünig E
    Arthritis Res Ther; 2019 Oct; 21(1):217. PubMed ID: 31655622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of ambrisentan in treatment of pulmonary arterial hypertension: a pilot study with 15 patients].
    He J; Wen L; Jiang R; Zhao QH; Wang L; Jiang X; Yan P; Bai L; Jing ZC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Jun; 41(6):493-6. PubMed ID: 24113042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
    Zhao Q; Guo N; Chen J; Parks D; Tian Z
    J Clin Pharm Ther; 2022 Feb; 47(2):146-156. PubMed ID: 34319626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric Population Pharmacokinetic Modeling and Exposure-Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data.
    Okour M; Thapar MM; Farrell C; Lukas MA; Beghetti M; Beerahee M
    J Clin Pharmacol; 2023 May; 63(5):593-603. PubMed ID: 36579617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of pulmonary arterial hypertension: role of ambrisentan.
    Barst RJ
    Vasc Health Risk Manag; 2007; 3(1):11-22. PubMed ID: 17583171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report).
    Takahashi T; Hayata S; Kobayashi A; Onaka Y; Ebihara T; Hara T
    Clin Drug Investig; 2018 Mar; 38(3):219-229. PubMed ID: 29282676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial.
    Preston IR; Burger CD; Bartolome S; Safdar Z; Krowka M; Sood N; Ford HJ; Battarjee WF; Chakinala MM; Gomberg-Maitland M; Hill NS
    J Heart Lung Transplant; 2020 May; 39(5):464-472. PubMed ID: 32008947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ambrisentan and its role in the management of pulmonary arterial hypertension.
    Macintyre IM; Dhaun N; Goddard J; Webb DJ
    Drugs Today (Barc); 2008 Dec; 44(12):875-85. PubMed ID: 19198697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.